Abstract
Trifluoperazine, a commonly used antipsychotic drug, has been known to induce QT prolongation and torsades de pointes, which can cause sudden death. We studied the effects of trifluoperazine on the human ether-a-go-go-related gene (HERG) channel expressed in Xenopus oocytes and on the delayed rectifier K+ current of guinea pig cardiomyocytes. The application of trifluoperazine showed a dose-dependent decrease in current amplitudes at the end of voltage steps and tail currents of HERG. The IC50 for a trifluoperazine block of HERG current progressively decreased according to depolarization: IC50 values at –40, 0, and +40 mV were 21.6, 16.6, and 9.29 μM, respectively. The voltage dependence of the block could be fitted with a monoexponential function, and the fractional electrical distance was estimated to be δ = 0.65. The block of HERG by trifluoperazine was use-dependent, exhibiting more rapid onset and greater steady-state block at higher frequencies of activation; there was partial relief of the block with decreasing frequency. In guinea pig ventricular myocytes, bath applications of 0.5 and 2 μM trifluoperazine at 36°C blocked the rapidly activating delayed rectifier K+ current by 32.4 and 72.9%, respectively; however, the same concentrations of trifluoperazine failed to significantly block the slowly activating delayed rectifier K+ current. Our findings suggest the arrhythmogenic side effect of trifluoperazine is caused by a blockade of HERG and the rapid component of the delayed rectifier K+ current rather than by the blockade of the slow component.
Footnotes
-
This work was supported by the Korea Research Foundation Grant R04-2003-000-10007-0 and by the Cheju National University Hospital Research Fund Grant (2004).
-
doi:10.1124/jpet.104.080853.
-
ABBREVIATIONS: QTc, rate-corrected QT interval; IKr, rapidly activating delayed rectifier K+ current; IKs, slowly activating delayed rectifier K+ current; HERG, human ether-a-go-go-related gene; LQT, long QT syndrome; APD, action potential duration; Itail, tail current(s); IHERG, current at the end of voltage step; E-4031, (1-[2-(6-methyl-2-pyridyl)ethyl]-4-methylsulfonylaminobenzoyl)-piperidine); BRL-32872, N-(3,4-dimethoxyphenyl)-N-[3[2-(3,4-dimethoxyphenyl)ethyl]propyl]-4-nitrobenzamide hydrochloride; TFZ, trifluoperazine.
- Received November 23, 2004.
- Accepted February 17, 2005.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|